Antibe Therapeutics Inc. announced that it received verbal notice on the afternoon of March 28, 2024 from the U.S. Food and Drug Administration that otenaproxesul has been placed on clinical hold, postponing the initiation of the planned Phase II trial. Antie expects to receive a formal Clinical Hold Letter from the FDA within 30 days outlining their rationale and further details.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.295 CAD | -.--% | -.--% | -68.28% |
24/04 | Antibe Therapeutics Inc. Announces Board Resignations | CI |
19/04 | Antibe Therapeutics Seeks Extension of Stay of Proceedings | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-68.28% | 11.45M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- ATE Stock
- News Antibe Therapeutics Inc.
- Antibe Therapeutics Inc. Announces FDA Clinical Hold on Otenaproxesul